LRIG1 is a triple threat: ERBB negative regulator, intestinal stem cell marker and tumour suppressor.
about
In vivo analysis of Lrig genes reveals redundant and independent functions in the inner earInducible loss of one Apc allele in Lrig1-expressing progenitor cells results in multiple distal colonic tumors with features of familial adenomatous polyposis.The LRIG family: enigmatic regulators of growth factor receptor signaling.Soluble LRIG2 ectodomain is released from glioblastoma cells and promotes the proliferation and inhibits the apoptosis of glioblastoma cells in vitro and in vivo in a similar manner to the full-length LRIG2Emerging understanding of multiscale tumor heterogeneityVitamin D is a determinant of mouse intestinal Lgr5 stem cell functionsDifferentially expressed transcripts and dysregulated signaling pathways and networks in African American breast cancer.Loss of Lrig1 leads to expansion of Brunner glands followed by duodenal adenomas with gastric metaplasia.LRIG and cancer prognosis.LRIG1 opposes epithelial-to-mesenchymal transition and inhibits invasion of basal-like breast cancer cells.Expression of LRIG1 is associated with good prognosis and human papillomavirus status in oropharyngeal cancer.Urofacial syndrome: a genetic and congenital disease of aberrant urinary bladder innervation.Non-Small Cell Lung Cancer Radiogenomics Map Identifies Relationships between Molecular and Imaging Phenotypes with Prognostic Implications.Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications.Environmental Impact on Intestinal Stem Cell Functions in Mucosal Homeostasis and Tumorigenesis.LRIG1 is a prognostic biomarker in non-small cell lung cancer.EGF receptor family: twisting targets for improved cancer therapies.Identification of six cell surface proteins for specific liver targeting.Overexpression of LRIG1 regulates PTEN via MAPK/MEK signaling pathway in esophageal squamous cell carcinomaOverexpression of epigen during embryonic development induces reversible, epidermal growth factor receptor-dependent sebaceous gland hyperplasia.The negative regulation of miR-149-5p in melanoma cell survival and apoptosis by targeting LRIG2.DNA methylation aberrancies delineate clinically distinct subsets of colorectal cancer and provide novel targets for epigenetic therapies.Lrig1+ gastric isthmal progenitor cells restore normal gastric lineage cells during damage recovery in adult mouse stomach.Downregulation of leucine-rich repeats and immunoglobulin-like domains 1 by microRNA-20a modulates gastric cancer multidrug resistance.LRIG1 negatively regulates RET mutants and is downregulated in thyroid cancer.Essential Role of Linx/Islr2 in the Development of the Forebrain Anterior Commissure.Isoliquiritigenin suppresses human melanoma growth by targeting miR-301b/LRIG1 signaling
P2860
Q27320101-B1CB0DEB-80E5-4117-8DDF-AB322FD45233Q33840012-CB960E35-F729-4BC7-A938-80758B6CAD3AQ34276176-E580F218-3636-4A3B-B166-E11D01D86DCBQ34421021-567E45D5-AB64-48EB-99AE-7FF1E9300F9DQ34730000-21E010E8-FB21-487C-AB66-E4963E6CC136Q35003527-85FE5D32-16EC-4A9F-93EB-54789E1D9104Q35064200-3DED7001-6F39-43A9-A102-83182099D6EBQ35236469-CD431747-7E40-4B18-81C7-9AD3AED31527Q35626430-EFEEA260-6FCF-44E1-A8CC-9F9F2794E97FQ36723368-C5C8B7D2-6616-4D6C-A49D-1B4723891869Q37681779-802AB01B-E716-4ED9-9ECE-FFD9E0CC390DQ38119849-206B5CB4-7C5E-4DD4-BDF5-621EB83878D1Q38373627-79927396-20E5-41A8-A473-E8AEB1686C76Q38794338-724FEA96-8368-4358-B080-4D0AC8F94190Q38943802-3EC24896-6C57-4A99-A1AD-A0F94CE06388Q39024741-028A6EAD-C1E1-4D97-AC87-29DC56AEF3FFQ39228711-1825F42B-251E-44DA-BFEB-ABA76CEE01BDQ41147332-8B0CA945-E834-4BCC-BA7A-AD189B96D80EQ41198043-B3C77414-74A8-4C8F-AE10-4F190A385893Q41861966-EEBE7292-02F2-46BF-8110-D3FF9525E6CEQ42367926-A1B353FA-EAE1-4AED-9311-14990F22C12CQ46181764-A370C664-AFB1-49CC-8E6B-BBAC9E795D56Q47302381-9D4D457F-18EC-4335-9B66-111EF393DF64Q49945042-B75FFF0A-E0CE-4D8D-9B35-131214B01413Q50047531-47D80BC5-FFCA-4001-A431-D0B61F5E323BQ54979521-33BA14D8-5A2D-49E1-9E26-E6FCE261A2A7Q58798829-EF4878B0-7AC6-4366-86BA-A54DCD16B4DC
P2860
LRIG1 is a triple threat: ERBB negative regulator, intestinal stem cell marker and tumour suppressor.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
LRIG1 is a triple threat: ERBB ...... marker and tumour suppressor.
@en
type
label
LRIG1 is a triple threat: ERBB ...... marker and tumour suppressor.
@en
prefLabel
LRIG1 is a triple threat: ERBB ...... marker and tumour suppressor.
@en
P2093
P2860
P921
P356
P1476
LRIG1 is a triple threat: ERBB ...... marker and tumour suppressor.
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.2013.138
P407
P5008
P577
2013-04-04T00:00:00Z
2013-05-14T00:00:00Z
P5875
P6179
1047057094